“In regards to the support of the pharmaceutical and biotechnology fields, Korean drugs should be preferentially treated”

At a meeting with the National Health Insurance Service and Health Insurance Review & Assessment Service journalists on the 26^th, Korea Pharmaceutical and Bio-Pharma Manufacturers Association(KPBMA) Chairman Hee-Mok Won emphasized importance of the ‘predictable and rational health insurance benefit system’ to foster Korean pharmaceutical and biotechnology companies as global company.

Chairman ...